University of Cape Town news story
New research has found that the real-world impact of late-stage TB vaccines may depend heavily on how well they protect against infectious, asymptomatic TB.
Up to half of all people with active TB may be asymptomatic, meaning a large proportion of transmission could be coming from individuals who do not yet feel ill. This “silent reservoir” is a key challenge for global TB control efforts — and a critical consideration for vaccine development.
Two promising TB vaccine candidates, M72/AS01E and MTBVAC, are currently in Phase 3 trials. While both have shown encouraging results so far, their long-term population impact remains uncertain. This study set out to better understand that potential by examining how vaccine impact might vary depending on which stages of TB disease they prevent.
Read the full news story here.
For more TB updates, check out the TB CAB Weekly Newsletter (Issue #8, 11 March 2026).
The newsletter is brought to you by the Global TB Community Advisory Board (TB CAB) with the support of Treatment Action Group (TAG) and the European AIDS Treatment Group (EATG). Subscribe to the newsletter here.
Source : University of Cape Town
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.